Compare AAME & CTSO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | AAME | CTSO |
|---|---|---|
| Founded | 1968 | 1997 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Life Insurance | Medical/Dental Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 54.7M | 45.7M |
| IPO Year | 1995 | 2008 |
| Metric | AAME | CTSO |
|---|---|---|
| Price | $2.53 | $0.56 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $5.38 |
| AVG Volume (30 Days) | 6.2K | ★ 87.8K |
| Earning Date | 05-12-2026 | 03-25-2026 |
| Dividend Yield | ★ 0.84% | N/A |
| EPS Growth | N/A | ★ 65.79 |
| EPS | ★ 0.22 | N/A |
| Revenue | ★ $188,227,000.00 | $22,503,908.00 |
| Revenue This Year | N/A | $12.21 |
| Revenue Next Year | N/A | $20.37 |
| P/E Ratio | $10.86 | ★ N/A |
| Revenue Growth | 0.77 | ★ 48.53 |
| 52 Week Low | $1.26 | $0.50 |
| 52 Week High | $3.71 | $1.39 |
| Indicator | AAME | CTSO |
|---|---|---|
| Relative Strength Index (RSI) | 46.39 | 33.03 |
| Support Level | $2.54 | N/A |
| Resistance Level | $2.63 | $0.74 |
| Average True Range (ATR) | 0.15 | 0.07 |
| MACD | -0.02 | -0.02 |
| Stochastic Oscillator | 32.69 | 23.86 |
Atlantic American Corp operates in specialty markets within the life and health and property and casualty insurance industries. The company has two segments: American Southern, It provides property and casualty insurance including bodily injury and property damage liability coverage, uninsured motorist coverage, and physical damage coverage for commercial accounts, and Bankers Fidelity, the company's life and health operations offer a variety of life and supplemental health products including ordinary and term life insurance, Medicare supplement, and other health insurance.
CytoSorbents Corp specializes in treating life-threatening conditions in intensive care and cardiac surgery using proprietary polymer adsorption technology. Its flagship product, CytoSorb, is approved in the EU as an extracorporeal cytokine absorber, aiming to reduce inflammation and prevent multiple organ failure in critical illnesses like sepsis and trauma. Revenue primarily comes from product sales in Germany, with additional income from grant agencies in the United States. The company operates through Direct sales and Distributors/strategic partners in United States, Germany and Other Countries. The company's product consists of Cytosorb, ECOS-300CY, VetResQ, HemoDefend, and DrugSorb-ATR.